Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial. (linkinghub.elsevier.com)

Authors: Bahner F … Sahin U Journal: Lancet Infectious Diseases Published: 2026-06-03 DOI: https://doi.org/10.1016/S1473-3099(26)00177-5